Lupus Nephritis: Induction Therapy in Severe Lupus Nephritis—Should MMF Be Considered the Drug of Choice?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lupus Nephritis: Induction Therapy in Severe Lupus Nephritis—Should MMF Be Considered the Drug of Choice?

Published:2012-08-09 Issue:1 Volume:8 Page:147-153
ISSN:1555-9041
Container-title:Clinical Journal of the American Society of Nephrology
language:en
Short-container-title:CJASN

Author:

Rovin Brad H.,Parikh Samir V.,Hebert Lee A.,Chan Tak Mao,Mok Chi Chiu,Ginzler Ellen M.,Hooi Lai Seong,Brunetta Paul,Maciuca Romeo,Solomons Neil

Publisher

American Society of Nephrology (ASN)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

Reference32 articles.

1. Therapy of Lupus Nephritis

2. Effect of treatment on the evolution of renal abnormalities in lupus nephritis;Balow;N Engl J Med,1984

3. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis

4. Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

5. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppressive drug therapy;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova;Nephrology and Dialysis;2024-08-13

3. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS;Kidney International;2024-01

4. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases;American Journal of Kidney Diseases;2023-08

5. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents;Clinical Immunology;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3